Research Progress on CLDN18.2 in Advanced Gastric Cancer
Tight junction protein CLDN18.2 is expressed in normal gastric mucosal epithelial cells and also in solid tumors such as gastric,colon,and pancreatic cancers,which is a potential ther-apeutic target for digestive system tumors.Various targeted therapies against CLDN18.2 have been designed,including monoclonal antibody,chimeric antigen receptor T-cell therapy(CAR-T),bis-pecific antibody,and antibody-drug conjugate.Currently,clinical trials of several CLDN18.2-tar-geting drugs are ongoing,among which trials of Zolbetuximab have been advanced most.This paper provides a comprehensive review of research progress on CLDN18.2 and its applications in advanced gastric cancer.
NETL
NSTL
万方数据
